Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs: Averting Cytotoxicity by Alloreactive T Lymphocytes

K. Haga, N. A. Lemp, C. R. Logg, J. Nagashima, E. Faure-Kumar, G. G. Gomez, C. A. Kruse, R. Mendez, R. Stripecke, Noriyuki Kasahara, J. C. Cicciarelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Transplantation of many tissues requires histocompatibility matching of human leukocyte antigens (HLA) to prevent graft rejection, to reduce the level of immunosuppression needed to maintain graft survival, and to minimize the risk of graft-versus-host disease, particularly in the case of bone marrow transplantation. However, recent advances in fields of gene delivery and genetic regulation technologies have opened the possibility of engineering grafts that display reduced levels of HLA expression. Suppression of HLA expression could help to overcome the limitations imposed by extensive HLA polymorphisms that restrict the availability of suitable donors, necessitate the maintenance of large donor registries, and complicate the logistics of procuring and delivering matched tissues and organs to the recipient. Accordingly, we investigated whether knockdown of HLA by RNA interference (RNAi), a ubiquitous regulatory system that can efficiently and selectively inhibit the expression of specific gene products, would enable allogeneic cells to evade immune recognition. For efficient and stable delivery of short hairpin-type RNAi constructs (shRNA), we employed lentivirus-based gene transfer vectors, which provide a delivery system that can achieve integration into genomic DNA, thereby permanently modifying transduced graft cells. Our results show that lentivirus-mediated delivery of shRNA targeting pan-Class I and allele-specific HLA can achieve efficient and dose-dependent reduction in surface expression of HLA in human cells, associated with enhanced resistance to alloreactive T lymphocyte-mediated cytotoxicity, while avoiding MHC-non-restricted killing. We hypothesize that RNAi-induced silencing of HLA expression has the potential to create histocompatibility-enhanced, and, eventually, perhaps "universally" compatible cellular grafts.

Original languageEnglish (US)
Pages (from-to)3184-3188
Number of pages5
JournalTransplantation Proceedings
Volume38
Issue number10
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Lentivirus
HLA Antigens
RNA Interference
T-Lymphocytes
Histocompatibility
Transplants
Tissue Transplantation
Graft Rejection
Graft vs Host Disease
Graft Survival
Bone Marrow Transplantation
Immunosuppression
Small Interfering RNA
Genes
Registries
Alleles
Technology
Gene Expression
DNA

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs : Averting Cytotoxicity by Alloreactive T Lymphocytes. / Haga, K.; Lemp, N. A.; Logg, C. R.; Nagashima, J.; Faure-Kumar, E.; Gomez, G. G.; Kruse, C. A.; Mendez, R.; Stripecke, R.; Kasahara, Noriyuki; Cicciarelli, J. C.

In: Transplantation Proceedings, Vol. 38, No. 10, 12.2006, p. 3184-3188.

Research output: Contribution to journalArticle

Haga, K, Lemp, NA, Logg, CR, Nagashima, J, Faure-Kumar, E, Gomez, GG, Kruse, CA, Mendez, R, Stripecke, R, Kasahara, N & Cicciarelli, JC 2006, 'Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs: Averting Cytotoxicity by Alloreactive T Lymphocytes', Transplantation Proceedings, vol. 38, no. 10, pp. 3184-3188. https://doi.org/10.1016/j.transproceed.2006.10.158
Haga, K. ; Lemp, N. A. ; Logg, C. R. ; Nagashima, J. ; Faure-Kumar, E. ; Gomez, G. G. ; Kruse, C. A. ; Mendez, R. ; Stripecke, R. ; Kasahara, Noriyuki ; Cicciarelli, J. C. / Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs : Averting Cytotoxicity by Alloreactive T Lymphocytes. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 10. pp. 3184-3188.
@article{2b0977a825a84378a006c6762da0f052,
title = "Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs: Averting Cytotoxicity by Alloreactive T Lymphocytes",
abstract = "Transplantation of many tissues requires histocompatibility matching of human leukocyte antigens (HLA) to prevent graft rejection, to reduce the level of immunosuppression needed to maintain graft survival, and to minimize the risk of graft-versus-host disease, particularly in the case of bone marrow transplantation. However, recent advances in fields of gene delivery and genetic regulation technologies have opened the possibility of engineering grafts that display reduced levels of HLA expression. Suppression of HLA expression could help to overcome the limitations imposed by extensive HLA polymorphisms that restrict the availability of suitable donors, necessitate the maintenance of large donor registries, and complicate the logistics of procuring and delivering matched tissues and organs to the recipient. Accordingly, we investigated whether knockdown of HLA by RNA interference (RNAi), a ubiquitous regulatory system that can efficiently and selectively inhibit the expression of specific gene products, would enable allogeneic cells to evade immune recognition. For efficient and stable delivery of short hairpin-type RNAi constructs (shRNA), we employed lentivirus-based gene transfer vectors, which provide a delivery system that can achieve integration into genomic DNA, thereby permanently modifying transduced graft cells. Our results show that lentivirus-mediated delivery of shRNA targeting pan-Class I and allele-specific HLA can achieve efficient and dose-dependent reduction in surface expression of HLA in human cells, associated with enhanced resistance to alloreactive T lymphocyte-mediated cytotoxicity, while avoiding MHC-non-restricted killing. We hypothesize that RNAi-induced silencing of HLA expression has the potential to create histocompatibility-enhanced, and, eventually, perhaps {"}universally{"} compatible cellular grafts.",
author = "K. Haga and Lemp, {N. A.} and Logg, {C. R.} and J. Nagashima and E. Faure-Kumar and Gomez, {G. G.} and Kruse, {C. A.} and R. Mendez and R. Stripecke and Noriyuki Kasahara and Cicciarelli, {J. C.}",
year = "2006",
month = "12",
doi = "10.1016/j.transproceed.2006.10.158",
language = "English (US)",
volume = "38",
pages = "3184--3188",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs

T2 - Averting Cytotoxicity by Alloreactive T Lymphocytes

AU - Haga, K.

AU - Lemp, N. A.

AU - Logg, C. R.

AU - Nagashima, J.

AU - Faure-Kumar, E.

AU - Gomez, G. G.

AU - Kruse, C. A.

AU - Mendez, R.

AU - Stripecke, R.

AU - Kasahara, Noriyuki

AU - Cicciarelli, J. C.

PY - 2006/12

Y1 - 2006/12

N2 - Transplantation of many tissues requires histocompatibility matching of human leukocyte antigens (HLA) to prevent graft rejection, to reduce the level of immunosuppression needed to maintain graft survival, and to minimize the risk of graft-versus-host disease, particularly in the case of bone marrow transplantation. However, recent advances in fields of gene delivery and genetic regulation technologies have opened the possibility of engineering grafts that display reduced levels of HLA expression. Suppression of HLA expression could help to overcome the limitations imposed by extensive HLA polymorphisms that restrict the availability of suitable donors, necessitate the maintenance of large donor registries, and complicate the logistics of procuring and delivering matched tissues and organs to the recipient. Accordingly, we investigated whether knockdown of HLA by RNA interference (RNAi), a ubiquitous regulatory system that can efficiently and selectively inhibit the expression of specific gene products, would enable allogeneic cells to evade immune recognition. For efficient and stable delivery of short hairpin-type RNAi constructs (shRNA), we employed lentivirus-based gene transfer vectors, which provide a delivery system that can achieve integration into genomic DNA, thereby permanently modifying transduced graft cells. Our results show that lentivirus-mediated delivery of shRNA targeting pan-Class I and allele-specific HLA can achieve efficient and dose-dependent reduction in surface expression of HLA in human cells, associated with enhanced resistance to alloreactive T lymphocyte-mediated cytotoxicity, while avoiding MHC-non-restricted killing. We hypothesize that RNAi-induced silencing of HLA expression has the potential to create histocompatibility-enhanced, and, eventually, perhaps "universally" compatible cellular grafts.

AB - Transplantation of many tissues requires histocompatibility matching of human leukocyte antigens (HLA) to prevent graft rejection, to reduce the level of immunosuppression needed to maintain graft survival, and to minimize the risk of graft-versus-host disease, particularly in the case of bone marrow transplantation. However, recent advances in fields of gene delivery and genetic regulation technologies have opened the possibility of engineering grafts that display reduced levels of HLA expression. Suppression of HLA expression could help to overcome the limitations imposed by extensive HLA polymorphisms that restrict the availability of suitable donors, necessitate the maintenance of large donor registries, and complicate the logistics of procuring and delivering matched tissues and organs to the recipient. Accordingly, we investigated whether knockdown of HLA by RNA interference (RNAi), a ubiquitous regulatory system that can efficiently and selectively inhibit the expression of specific gene products, would enable allogeneic cells to evade immune recognition. For efficient and stable delivery of short hairpin-type RNAi constructs (shRNA), we employed lentivirus-based gene transfer vectors, which provide a delivery system that can achieve integration into genomic DNA, thereby permanently modifying transduced graft cells. Our results show that lentivirus-mediated delivery of shRNA targeting pan-Class I and allele-specific HLA can achieve efficient and dose-dependent reduction in surface expression of HLA in human cells, associated with enhanced resistance to alloreactive T lymphocyte-mediated cytotoxicity, while avoiding MHC-non-restricted killing. We hypothesize that RNAi-induced silencing of HLA expression has the potential to create histocompatibility-enhanced, and, eventually, perhaps "universally" compatible cellular grafts.

UR - http://www.scopus.com/inward/record.url?scp=33845445620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845445620&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.10.158

DO - 10.1016/j.transproceed.2006.10.158

M3 - Article

C2 - 17175217

AN - SCOPUS:33845445620

VL - 38

SP - 3184

EP - 3188

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -